Kymera Therapeutics, Inc. (KYMR)

Nasdaq · Healthcare · Biotechnology
$115.31-3.42%As of 2026-11-22 · USD
Last session low $114.39Last session high $119.56
52-week low $63.6952-week high $142.92
Market cap
$9.84B
Sector
Healthcare

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)40.6In the neutral range (30 to 70)
MACD (12, 26, 9)1.12Below its signal line (3.25); histogram -2.13
Bollinger %B (20, 2)10%Inside the bands (112.44 to 139.83)
SMA 20126.13Price is 8.6% below
SMA 50117.56Price is 1.9% below
SMA 200100.57Price is 14.7% above
ATR (20)5.48% of priceAverage true range per day
52-week position65%In the middle of the 63.69 to 142.92 range

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.

Insider filings, 90 daysNo purchases and 1 sale (about $744K).
Latest fiscal yearEnded 2025-12-31: revenue of $39.21M and an operating margin of -881.2%.

More in Biotechnology